Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Bolsa de Madrid  >  Almirall, S.A.    ALM   ES0157097017

ALMIRALL, S.A.

(ALM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Almirall S A : Volker Koscielny, new Chief Medical Officer and new member of the Management Board at Almirall

share with twitter share with LinkedIn share with facebook
share via e-mail
12/03/2019 | 08:28am EST

Barcelona, Spain
December 3rd, 2019

Almirall, S.A. (ALM) has announced the appointment of Volker Koscielny as the new Chief Medical Officer and member of the Management Board of the company.

In his new role, Volker Koscienly will report directly to Peter Guenter, Chief Executive Officer of Almirall, and will be driving the overarching Medical Affairs strategy providing guidance to the Medical department, fostering medical innovation and ensuring safe and appropriate use of all our products.

'Reinforcing the medical department is a strategic imperative given our launches of increasingly innovative products and our exciting pipeline', explained Peter Guenter, Chief Executive Officer, Almirall. 'Volker will join us with experience from leading pharmaceutical companies and with extensive experience in dermatology. Being able to attract somebody of the caliber of Volker underlines Almirall's attractiveness'.

In his last position as Vice President Medical Affairs at Celgene Worldwide Markets (ex-US), based in Switzerland, Volker was instrumental in designing and building the inflammation franchise up from inception and for supporting the ongoing development and launch of Apremilast in plaque psoriasis. Moreover, he played a key role in developing and executing the ex-US real world evidence study programme, that underpinned the success of Apremilast in Europe today.

Before joining Celgene, Volker held positions of increasing seniority in several pharmaceutical companies both in medical and commercial positions in the UK, France and South Africa having local and regional responsibilities across multiple therapeutic areas.

Volker has a particular interest in understanding patient needs and in demonstrating the value of medicines to patients and healthcare systems in the real world. His solid clinical, academic and scientific background, together with his experience in leading large teams and his results orientated mindset, will provide Almirall with a fresh and valuable perspective.

'There is huge unmet need in medical dermatology, with many diseases lacking effective and innovative therapies. I am privileged to be joining an organization that is committed to addressing these areas, aiming to make significant difference to patients' lives. Almirall today has one of the most exciting and innovative pipelines in medical dermatology and I am looking forward to be joining a team of top professionals to deliver the promise of the product pipeline', added Dr. Koscielny.

Volker trained as a doctor at the Charité in Berlin - one of the largest university hospitals in Europe - and practiced internal medicine in Germany, his home country. He holds a doctorate in Neuropathology and an MBA from the University of Durham (UK). He will be based in Barcelona, Spain.

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals by continuous improvement, bringing our innovative solutions where they are needed.

The company, founded almost 75 years ago with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has been key in value creation to society according to its commitment with to major shareholders and through its decision to help others, to understand their challenges and to use Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. More than 1,800 employees are devoted to Science.

For more information, please visit almirall.com

Disclaimer

Almirall SA published this content on 03 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 December 2019 13:27:00 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALMIRALL, S.A.
02/19ALMIRALL, S.A. : annual earnings release
02/06ALMIRALL S A : partners with Plug and Play to accelerate digital innovation in d..
PU
01/15ALMIRALL S A : to participate in J.P. Morgan Healthcare Conference in San Franci..
PU
01/09ALMIRALL S A : signs a strategic agreement with 23andMe to license rights of a b..
PU
01/09ALMIRALL S A : and WuXi Biologics sign strategic collaboration agreement for mul..
PU
01/08ALMIRALL S A : enters into an option agreement to acquire Bioniz Therapeutics an..
PU
2019ALMIRALL S A : and Iktos announce research collaboration in Artificial Intellige..
PU
2019ALMIRALL S A : Volker Koscielny, new Chief Medical Officer and new member of the..
PU
2019GLOBAL MARKETS LIVE : Tencent, Alibaba, Boeing, Apple…
2019ALMIRALL : Exercises its Option with Dermira to License Rights to Lebrikizumab i..
AQ
More news
Financials (EUR)
Sales 2019 881 M
EBIT 2019 176 M
Net income 2019 120 M
Debt 2019 414 M
Yield 2019 1,59%
P/E ratio 2019 19,5x
P/E ratio 2020 17,9x
EV / Sales2019 3,05x
EV / Sales2020 2,79x
Capitalization 2 269 M
Chart ALMIRALL, S.A.
Duration : Period :
Almirall, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALMIRALL, S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 19,11  €
Last Close Price 13,00  €
Spread / Highest target 53,8%
Spread / Average Target 47,0%
Spread / Lowest Target 26,9%
EPS Revisions
Managers
NameTitle
Peter Guenter Chief Executive Officer & Director
Jorge Gallardo Ballart Chairman
Michael McClellan Chief Financial Officer
Eloi Crespo Cervera Vice President-Manufacturing & Technical Services
Bhushan D. Hardas Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL, S.A.-11.00%2 455
JOHNSON & JOHNSON2.24%392 415
ROCHE HOLDING AG10.05%303 192
NOVARTIS3.81%220 641
MERCK AND COMPANY-9.84%208 771
PFIZER-7.30%200 501